JYNNEOS

BIOLOGICAL5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Womack Army Medical Center, University of Alabama at Birmingham, Bavarian Nordic

Conditions

HIVImmune DysregulationInjection Drug UseMonkeypoxMonkeypox (Mpox)MyopericarditisSmall PoxSystemic Inflammation

Phase 2

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

CompletedNCT05512949

National Institute of Allergy and Infectious Diseases (NIAID)Monkeypox

Start: 2022-09-09End: 2025-02-24Updated: 2026-04-16

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

CompletedNCT05740982

National Institute of Allergy and Infectious Diseases (NIAID)Monkeypox

Start: 2023-03-22End: 2024-08-28Updated: 2026-03-27

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

Active, not recruitingNCT07199569

Bavarian NordicMonkeypox (Mpox)

Start: 2025-10-27End: 2026-11-30Updated: 2026-04-08

Phase 4

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

RecruitingNCT06829238

University of Alabama at BirminghamHIV, Immune Dysregulation, Injection Drug Use +1

Start: 2025-04-07End: 2029-11-30Target: 100Updated: 2026-04-22

Unknown Phase

Assessment of Myocarditis After Replication-Deficient Smallpox Immunization

Not yet recruitingNCT05513313

Womack Army Medical CenterMyopericarditis, Small Pox

Start: 2029-03-31End: 2033-10-31Target: 2350Updated: 2023-12-14

Related Papers

Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination.

2025-11-29

579. Safety and Immunogenicity of Mpox Vaccination in Adolescents

Open Forum Infectious Diseases2025-01-292 citations